Skip to main content

Table 2 Robustness of the method for doxorubicin (DOX)

From: Enhancement of oral bioavailability of doxorubicin through surface modified biodegradable polymeric nanoparticles

(a) Robustness

Conditions

LQC (2.90 ng/ml)

MQC(1000 ng/ml)

HQC (2000 ng/ml)

Mobile phase [ACN: 0.1% formic acid (50:50: v/v)]

 Negative level (49.9:50.10, n = 3)

2.70 ± 0.11 (4.07%)

970.10 ± 11.01 (1.13%)

1967.89 ± 15.09 (0.77%)

 Zero level (50:50, n = 3)

2.84 ± 0.02 (0.70%)

981.89 ± 13.99 (1.42%)

1988.99 ± 11.89 (0.60%)

 Positive level (50.10:49.90, n = 3)

2.75 ± 0.12 (4.36%)

974.91 ± 12.08 (1.24%)

1970.01 ± 14.09 (0.72%)

Flow rate (0.20 ml/min)

 Negative level (0.19, n = 3)

2.61 ± 0.09 (3.45%)

969.01 ± 11.33 (1.17%)

1971.61 ± 19.02 (0.96%)

 Zero level (0.20, n = 3)

2.79 ± 0.081 (2.90%)

988.78 ± 12.01 (1.21%)

1981.01 ± 12.91 (0.65%)

 Positive level (0.21, n = 3)

2.70 ± 0.12 (4.44%)

972.05 ± 10.56 (1.09%)

1967.29 ± 11.56 (0.59%)

pH of mobile phase (default pH = 7.2)

 Negative level (6.9, n = 3)

2.61 ± 0.061 (2.34%)

971.98 ± 5.99 (0.62%)

1968.45 ± 11.05 (0.56%)

 Zero level (7.2, n = 3)

2.84 ± 0.012 (0.42%)

985.11 ± 8.92 (0.91%)

1985.42 ± 10.66 (0.54%)

 Positive level (7.4, n = 3)

2.69 ± 0.058 (2.16%)

974.91 ± 6.30 (0.65%)

1977.00 ± 15.99 (0.81%)

(b) Ruggedness

QC ID

Theoretical content (ng/ml)

Mean concentration observed (ng/ml)

Accuracy a (%)

CV (%) b

LOQQC

1.01

0.95 ± 0.021

94.60

2.21

LQC

2.90

2.81 ± 0.088

96.90

3.13

MQC

1000.00

981.01 ± 9.33

98.10

0.95

HQC

2000.00

1979.01 ± 5.00

98.95

0.25

  1. Values (Mean ± SD) are derived from 6 replicates:
  2. a Accuracy (%) = Mean value of [(mean observed concentration)/(theoretical concentration)] × 100
  3. b Precision (%): coefficient of variance (percentage) = standard deviation divided by mean concentration found × 100; Theoretical contents; LOQQC: 1.01 ng/ml, LQC: 2.90 ng/ml; MQC: 1000 ng/ml; and HQC: 2000 ng/ml